Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04771897 · ClinicalTrials.gov registry record · Phase 1
A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
A Phase 1 study, sponsored by Bexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04771897 is a Phase 1 study that was terminated before completion, run by Bexion Pharmaceuticals. The registered enrollment target is 10 participants.
The verdict
NCT04771897, a Phase 1 study, was terminated before completion, sponsored by Bexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children with newly diagnosed DIPG or DMG. All patients will receive BXQ-350 by intravenous (IV) infusion and radiation therapy. The study is divided into two parts: Part 1 will enroll patients at increasing dose levels of BXQ-350 in order to determine the MTD. Part 2 will enroll patients requiring a biopsy in order to assess BXQ-350 concentrations in the biopsied tumor.
Interventions
- DRUG BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance
- DRUG BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2024-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04771897
The ClinicalTrials.gov registry entry for NCT04771897 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bexion Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance is the first listed.
NCT04771897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04771897 about?
NCT04771897 is a clinical study titled "A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)". This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children with newly diagnosed DIPG or DMG. All patients will receive BXQ-350 by intravenous (IV) infusion and radiation therapy. The study is divided into two parts: Part 1 will enroll patients at increa...
What is the current status of trial NCT04771897?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2021-05-24. Estimated completion is 2024-10-04.
What interventions are being tested in trial NCT04771897?
The interventions under investigation include: BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance (DRUG), BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations (DRUG).
Who is sponsoring clinical trial NCT04771897?
This trial is sponsored by Bexion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.